ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $63.82 million. The enterprise value is -$67.40 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ALXO has 52.74 million shares outstanding. The number of shares has increased by 24.48% in one year.
| Current Share Class | 52.74M |
| Shares Outstanding | 52.74M |
| Shares Change (YoY) | +24.48% |
| Shares Change (QoQ) | +1.66% |
| Owned by Insiders (%) | 2.09% |
| Owned by Institutions (%) | 56.37% |
| Float | 31.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.82 |
| Quick Ratio | 4.63 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -93.11 |
Financial Efficiency
Return on equity (ROE) is -98.94% and return on invested capital (ROIC) is -59.14%.
| Return on Equity (ROE) | -98.94% |
| Return on Assets (ROA) | -49.24% |
| Return on Capital (ROIC) | -59.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.10M |
| Employee Count | 72 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.26% in the last 52 weeks. The beta is 1.04, so ALXO's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | -87.26% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 7.85 |
| Relative Strength Index (RSI) | 28.77 |
| Average Volume (20 Days) | 871,533 |
Short Selling Information
The latest short interest is 7.84 million, so 14.87% of the outstanding shares have been sold short.
| Short Interest | 7.84M |
| Short Previous Month | 9.59M |
| Short % of Shares Out | 14.87% |
| Short % of Float | 25.20% |
| Short Ratio (days to cover) | 11.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -159.88M |
| Pretax Income | -166.20M |
| Net Income | -151.16M |
| EBITDA | -159.01M |
| EBIT | -159.88M |
| Earnings Per Share (EPS) | -$2.97 |
Full Income StatementBalance Sheet
The company has $148.57 million in cash and $17.36 million in debt, giving a net cash position of $131.22 million or $2.49 per share.
| Cash & Cash Equivalents | 148.57M |
| Total Debt | 17.36M |
| Net Cash | 131.22M |
| Net Cash Per Share | $2.49 |
| Equity (Book Value) | 136.81M |
| Book Value Per Share | 2.59 |
| Working Capital | 123.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$129.54 million and capital expenditures -$535,000, giving a free cash flow of -$130.08 million.
| Operating Cash Flow | -129.54M |
| Capital Expenditures | -535,000 |
| Free Cash Flow | -130.08M |
| FCF Per Share | -$2.47 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |